Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy
- PMID: 16467119
- DOI: 10.1158/1078-0432.CCR-05-2296
Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy
Abstract
Although endocrine therapy is highly effective in the treatment of endocrine receptor-positive breast cancer, chemotherapy has been shown to provide clinical benefit when added to tamoxifen. However, baseline risk after tamoxifen treatment is so low, especially in patients who are axillary node negative, that significant overtreatment will result if chemotherapy is given to every patient. Robust prognostic and predictive markers need to be developed to identify those at high risk of treatment failure. Although comprehensive gene expression profiling methods do offer promise, they require fresh or frozen tumor samples. To take advantage of existing archived tissue blocks with clinical follow-up collected from finished clinical trials, such as National Surgical Adjuvant Breast and Bowel Project trials B-20 and B-14, technologies that allow interrogation of archived blocks for gene expression profiling need to be realized. Recent developments in gene expression profiling technologies are discussed with their implications in clinical management of endocrine receptor-positive breast cancer.
Similar articles
-
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial.
-
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17. Breast Cancer Res. 2008. PMID: 18928543 Free PMC article.
-
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.Breast Cancer Res Treat. 2009 Aug;116(3):509-20. doi: 10.1007/s10549-008-0250-8. Epub 2008 Nov 20. Breast Cancer Res Treat. 2009. PMID: 19020972
-
Development of the 21-gene assay and its application in clinical practice and clinical trials.J Clin Oncol. 2008 Feb 10;26(5):721-8. doi: 10.1200/JCO.2007.15.1068. J Clin Oncol. 2008. PMID: 18258979 Review.
-
New molecular classifications of breast cancer.CA Cancer J Clin. 2009 Sep-Oct;59(5):303-13. doi: 10.3322/caac.20029. CA Cancer J Clin. 2009. PMID: 19729680 Review.
Cited by
-
Pathways to tamoxifen resistance.Cancer Lett. 2007 Oct 18;256(1):1-24. doi: 10.1016/j.canlet.2007.03.016. Epub 2007 May 1. Cancer Lett. 2007. PMID: 17475399 Free PMC article. Review.
-
Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL sample preparation.Breast Cancer Res Treat. 2011 Feb;125(3):879-83. doi: 10.1007/s10549-010-1159-6. Epub 2010 Sep 15. Breast Cancer Res Treat. 2011. PMID: 20842525 Free PMC article.
-
Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients.PLoS One. 2015 Apr 6;10(4):e0123194. doi: 10.1371/journal.pone.0123194. eCollection 2015. PLoS One. 2015. PMID: 25844937 Free PMC article.
-
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.BMC Cancer. 2010 Feb 9;10:37. doi: 10.1186/1471-2407-10-37. BMC Cancer. 2010. PMID: 20144231 Free PMC article. Clinical Trial.
-
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.BMC Cancer. 2007 Apr 3;7:59. doi: 10.1186/1471-2407-7-59. BMC Cancer. 2007. PMID: 17407600 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
